The characteristics and evolution of pulmonary fibrosis in COVID-19 patients as assessed by AI-assisted chest HRCT

Autor: Yong Jun Ding, Shi‑Ming Chen, Xiao Jing Jiang, Wen Cai Huang, Bin Ru Wang, Jia Ni Zou, Liu Sun, You Zou, Shan Xu, Li-Jun Shen
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
Viral Diseases
Pulmonology
Epidemiology
Pulmonary Fibrosis
Biochemistry
Severity of Illness Index
030218 nuclear medicine & medical imaging
0302 clinical medicine
Medical Conditions
Fibrosis
Risk Factors
Pulmonary fibrosis
Medicine and Health Sciences
Image Processing
Computer-Assisted
Medicine
Honeycombing
Immune Response
Optical Properties
Multidisciplinary
Incidence (epidemiology)
Middle Aged
Thorax
Patient Discharge
Infectious Diseases
Physical Sciences
Cardiology
Female
Thickening
Research Article
Opacity
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19)
Science
Immunology
Materials Science
Material Properties
03 medical and health sciences
Respiratory Disorders
Signs and Symptoms
Artificial Intelligence
Internal medicine
Albumins
Severity of illness
Humans
Inflammation
Bronchiectasis
business.industry
Interleukin-6
SARS-CoV-2
Biology and Life Sciences
Proteins
COVID-19
Covid 19
medicine.disease
030228 respiratory system
Medical Risk Factors
Respiratory Infections
Lesions
Clinical Medicine
business
Tomography
X-Ray Computed
Developmental Biology
Zdroj: PLoS ONE, Vol 16, Iss 3, p e0248957 (2021)
PLoS ONE
ISSN: 1932-6203
Popis: The characteristics and evolution of pulmonary fibrosis in patients with coronavirus disease 2019 (COVID-19) have not been adequately studied. AI-assisted chest high-resolution computed tomography (HRCT) was used to investigate the proportion of COVID-19 patients with pulmonary fibrosis, the relationship between the degree of fibrosis and the clinical classification of COVID-19, the characteristics of and risk factors for pulmonary fibrosis, and the evolution of pulmonary fibrosis after discharge. The incidence of pulmonary fibrosis in patients with severe or critical COVID-19 was significantly higher than that in patients with moderate COVID-19. There were significant differences in the degree of pulmonary inflammation and the extent of the affected area among patients with mild, moderate and severe pulmonary fibrosis. The IL-6 level in the acute stage and albumin level were independent risk factors for pulmonary fibrosis. Ground-glass opacities, linear opacities, interlobular septal thickening, reticulation, honeycombing, bronchiectasis and the extent of the affected area were significantly improved 30, 60 and 90 days after discharge compared with at discharge. The more severe the clinical classification of COVID-19, the more severe the residual pulmonary fibrosis was; however, in most patients, pulmonary fibrosis was improved or even resolved within 90 days after discharge.
Databáze: OpenAIRE
Externí odkaz: